April 2020

HCD keeps it together...virtually

Last Friday, HCD’s office administrator Liz won the newly launched HCD Friday pub quiz, with 13 points out of a possible 20. Quizmaster and General Manager, Peter Brown, launched the pub night following a suggestion from one of our Real World Evidence team. The pub uses Microsoft Teams to link all HCD staff, all of whom are now working from home. The conversation flows easily, with much laughter and leg pulling and everyone on the team now looks forward to the virtual Friday gathering, all having a glass or can of their chosen beverage in front of them to toast colleagues.
Read More
February 2020

Transformation in Haemophilia - the role of real world evidence in changing the treatment paradigm

The potential of gene therapy to transform treatment for patients with haemophilia is entering clinical practice. The literature in adeno-associated viral (AAV) vector-mediated gene therapy demonstrates improvement in endogenous factor levels over sustained periods, significant reduction in annualised bleed rates, lower exogenous factor usage and thus far a positive safety profile. Gene therapy is also associated improvements in the burden of illness for haemophilia patients as measured by HRQoL and economic analysis.
Read More
February 2020

Rare Disease Day 2020

Rare Disease Day 2020 - raising awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives. Rare Disease Day will be on February 29th 2020. As a research partner and advocate for the rare disease community, HCD Economics is sharing news of this event with our website community.
Read More
January 2020

HCD real world and medical affairs team report from ASH (American Society of Haematology 2019)

HCD’s Hayley Hubberstey, Real World Evidence Manager and Dr Harpal Dhillon, Global Medical Affairs Director attended ASH in December 2019 for the shared objective to learn the latest in terms of medical advances/understanding in HCD’s research areas of Sickle Cell Disease and Haemophilia and to identify 2020 research areas, that would benefit from the patient empowered methodology HCD has pioneered, alongside a need in the future research area to unearth evidence of burden of illness and provide expertise pro bono, in support of patient and political advocacy.
Read More
November 2019

Valuable news resource for researchers in Gaucher disease

The International Gaucher Alliance (IGA) publishes a regular monthly newsletter. In the November 2019 edition reports are filed from all parts of the IGA organisation, including established and emerging National members of the Gaucher community such as Belgium, Albania, Pakistan and the United States.
Read More